A0A6D2X6C5 (A0A6D2X6C5_PANTR) Pan troglodytes (Chimpanzee)
Proto-oncogene vav UniProtKBInterProInteractive Modelling
Available Structures
10 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Structural Basis of Promiscuous Guanine Nucleotide Exchange by the T-Cell Essential Vav1 |
Heteromer P15498; P63000; | 100.0 | 2×ZN; | |||
| Solution structure of the VAV1 SH2 domain complexed with a tyrosine-phosphorylated peptide from SLP… |
Heteromer P15498; Q13094; | 100 | ||||
| Solution structure of the Vav1 SH2 domain complexed with a Syk-derived doubly phosphorylated peptide |
Heteromer P15498; P48025; | 100 | ||||
| Solution structure of the Vav1 SH2 domain complexed with a Syk-derived singly phosphorylated peptide |
Heteromer P15498; P48025; | 100 | ||||
| Crystal structure of CRBN-DDB1 and MRT-23227 in complex with VAV1 |
Heteromer P15498; Q16531; Q96SW2; | 100 | 1×ZN; 1×A1BYX; | |||
| Vav1 inhibited by an allosteric inhibitor: Vav1 inhibitors block GEF activity | monomer | 100.0 | 1×9JY; 1×MES; 2×ZN; | |||
| Autoinhibited Vav1 | monomer | 99.81 | 2×ZN; | |||
| Apo structure of the activated truncation of Vav1 | monomer | 100.0 | 2×ZN; | |||
| Vav1 inhibited by an allosteric inhibitor: Vav1 inhibitors block GEF activity | monomer | 100.0 | 2×ZN; 1×9K1; | |||
| Solution structure of the SH2 domain of human proto-oncogene protein VAV1 | monomer | 91.67 | ||||
10 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6nf1.1.A | monomer | 0.84 | 1×9JY; 1×MES; 2×ZN; | 100.00 | ||
| 8tua.1.A | monomer | 0.66 | 28.80 | |||
| 7z3j.1.A | monomer | 0.59 | 30.91 | |||
| 8t7c.1.A | monomer | 0.57 | 30.41 | |||
| 8jqh.1.A | monomer | 0.56 | 30.41 | |||
| 2dvj.1.A | monomer | 0.56 | 29.70 | |||
| 2crh.1.A | monomer | 0.55 | 100.00 | |||
| 8dgo.1.A | monomer | 0.55 | 31.77 | |||
| 1opk.1.A | monomer | 0.53 | 32.12 | |||
| 2eyz.1.A | monomer | 0.52 | 29.52 | |||